Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Zacks Investment Research on MSN2d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
Zacks.com on MSN4d
PFE Secures EU Nod for Expanded Use of RSV Vaccine AbrysvoThe latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV vaccine, Abrysvo. The vaccine has been approved for the prevention of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback